I.[CH:2]([N:4]1[CH2:9][CH2:8][N:7]([C:10](=[NH:12])[NH2:11])[CH2:6][CH2:5]1)=[O:3].[O-]CC.[Na+].[NH2:17]N.[CH:19]1[CH:24]=[C:23]([C:25]([C:27]([C:29]2[N:34]=[CH:33][CH:32]=[CH:31][CH:30]=2)=O)=O)[N:22]=[CH:21][CH:20]=1>C(O)C>[CH:2]([N:4]1[CH2:9][CH2:8][N:7]([C:10]2[N:11]=[N:17][C:27]([C:29]3[CH:30]=[CH:31][CH:32]=[CH:33][N:34]=3)=[C:25]([C:23]3[CH:24]=[CH:19][CH:20]=[CH:21][N:22]=3)[N:12]=2)[CH2:6][CH2:5]1)=[O:3]A mixture of 4-formyl-piperazinecarboximidamide hydroiodide (prepared according to U.S. Pat. No. 4,351,832) in ethanol (4 ml) and ethanolic sodium ethoxide (1.4N, 6.8 ml) is stirred for 15 min and then anhydrous hydrazine (0.32 g) in ethanol (3 ml) is added. The mixture is stirred an additional 15 min, then 2,2'-pyridil (2.12 g) is added. The mixture is stirred for 12 hours at 25° and concentrated. The residue is chromatographed on silica gel eluting with a methylene chloride/methanol mixture. The appropriate fractions are pooled and concentrated to give 1-formyl 4-[5,6-bis(2-pyridinyl)-1,2,4-triazin-3-yl]-piperazine. Hydrolysis of the formamide in the usual way (PREPARATION A-14) give the title compound.
読み込み中…
